Krishna Yeshwant

Krishna Yeshwant is a Managing Partner at GV, where he co-leads the firm's life sciences group. He occupies a rare dual role, remaining an active internal medicine attending physician at Brigham and Women's Hospital in Boston while investing — giving him a frontline clinician's perspective alongside his venture work. The son of two Chicago physicians, his first love was actually computing: he majored in computer science at Stanford and, before medicine, co-founded two successful technology startups — an electronic data interchange company acquired by Hewlett-Packard and a network security company acquired by Symantec.

His path into medicine began around 2002, when he worked with surgeons at Massachusetts General Hospital and Brigham and Women's Hospital to write software that used imaging systems to guide surgical procedures. He went on to earn a combined MD/MBA from Harvard (Harvard Medical School and Harvard Business School) and completed his internal medicine residency at Brigham and Women's.

Yeshwant joined Google in 2008 and was part of the small team involved in GV's founding, where he championed and led the fund's early commitment to investing in life sciences — at a time when few generalist venture firms were building dedicated biotech practices. Today he helps steward the broader GV investing team and has built out the firm's life sciences incubation program, launching companies from the ground up rather than only backing existing ones.

• Invests across the full healthcare spectrum: care delivery, health IT, devices, diagnostics, payor/provider models, and therapeutics.
• Bridges biology and patient-facing software — pairing deep science with his own clinical experience and Google's early business-development playbook.
• Advocate for "new long-horizon science funding models," arguing (as he told Fortune) that the traditional way science is funded "is crazy" and needs rethinking for ambitious, curative research.
• In his own words on the current moment in biotech: *"We're in an era where we can see a path to not just treating, but curing more diseases."*
• Comfortable with risk and long time horizons — GV deploys large amounts of capital annually into scientifically risky bets, and Yeshwant both incubates new companies and invests at seed through growth stages.